ID   BT632
AC   CVCL_E6FS
SY   Ag1052; CPDM_0098X
RX   PubMed=34610309;
WW   Provider; CPDM; CPDM_0098X; https://docs.google.com/spreadsheets/d/1sxAPF3p6xK2h01zaiQ1ExCWwzhxeZ-oDLN3s3LeJq98/edit?usp=sharing
CC   Part of: Center for Patient Derived Models (CPDM) at Dana-Farber Cancer Institute cell line panel.
CC   Population: Caucasian.
CC   Characteristics: Can grow as a neurosphere (PubMed=34610309).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Trp53Ter (c.159G>A); ClinVar=VCV000420659; Zygosity=Unspecified (CPDM=CPDM_0098X).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg342Ter (c.1024C>T); ClinVar=VCV000182970; Zygosity=Unspecified (CPDM=CPDM_0098X).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Transcriptomics; RNAseq.
CC   Derived from site: In situ; Brain, right frontal cortex; UBERON=UBERON_0001870.
DI   NCIt; C39750; Glioblastoma, IDH-wildtype
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   66Y
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   PubMed=34610309; DOI=10.1016/j.celrep.2021.109788;
RA   Stockslager M.A., Malinowski S., Touat M., Yoon J.C., Geduldig J.,
RA   Mirza M., Kim A.S., Wen P.Y.-C., Chow K.-H., Ligon K.L., Manalis S.R.;
RT   "Functional drug susceptibility testing using single-cell mass
RT   predicts treatment outcome in patient-derived cancer neurosphere
RT   models.";
RL   Cell Rep. 37:109788.1-109788.12(2021).
//